A novel immunostimulatory OX40/PD-L1 bivalent bispecific antibody (MEDI1109) for the treatment of patients with cancer

被引：2
|
作者：
Oberst, Michael D. [1 ]
Kasturirangan, Srinath [1 ]
Sachs, Clifford [1 ]
Auge, Catherine [1 ]
Moynihan, James [1 ]
Rothstein, Raymond [1 ]
Hair, James [2 ]
Neal, Francis [2 ]
Mamidi, Srinivas [2 ]
Hanabuchi, Shino [1 ]
Watkins, Amanda [2 ]
Zheng, Yanan [3 ]
Rosenthal, Kim [1 ]
Freeman, Daniel J. [1 ]
Hammond, Scott [1 ]
机构：
[1] MedImmune, Gaithersburg, MD USA
[2] MedImmune, Liverpool, Merseyside, England
[3] MedImmune, San Francisco, CA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2775
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2775
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment
    Kuang, Zhihui
    Pu, Pu
    Wu, Min
    Wu, Zhihai
    Wang, Li
    Li, Yiming
    Zhang, Shaofei
    Jing, Hua
    Wu, Weiwei
    Chen, Bingliang
    Liu, Junjian
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (12) : 2564 - 2574
  • [2] The PD-L1 and OX40 bispecific antibody IBI327 induces immune activation and improves cancer immunotherapy
    Chen, Bingliang
    Kuang, Zhihui
    Li, Yiming
    Zhou, Shuaixiang
    Wu, Zhihai
    Wu, Min
    Yu, Michael
    Liu, Junjian
    CANCER RESEARCH, 2020, 80 (16)
  • [3] Differential expression of immune checkpoints (OX40/OX40L and PD-1/PD-L1) in decidua of unexplained recurrent spontaneous abortion women
    Qian, Chenyue
    Pan, Chenhuan
    Liu, Juanjuan
    Wu, Lijuan
    Pan, Jie
    Liu, Cuiping
    Zhang, Hong
    HUMAN IMMUNOLOGY, 2024, 85 (01)
  • [4] Urinary Cell Levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and Acute Rejection of Human Renal Allografts
    Afaneh, Cheguevara
    Muthukumar, Thangamani
    Lubetzky, Michelle
    Ding, Ruchuang
    Snopkowski, Catherine
    Sharma, Vijay K.
    Seshan, Surya
    Dadhania, Darshana
    Schwartz, Joseph E.
    Suthanthiran, Manikkam
    TRANSPLANTATION, 2010, 90 (12) : 1381 - 1387
  • [5] MEDI7526: a novel bispecific antibody that activates the CD40 pathway and down-regulates cell surface PD-L1 expression
    Wang, Yaya
    Turman, Sean
    Malhotra, Deepali
    Gilbreth, Ryan
    Wang, Yue
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Blockade of the OX40/OX40L pathway and induction of PD-L1 synergistically protects mouse islet allografts from rejection
    Li Tao
    Ma Rui
    Zhu Jiye
    Wang Fushun
    Huang Lei
    Leng Xisheng
    中华医学杂志（英文版）, 2014, (14) : 2686 - 2692
  • [7] Blockade of the OX40/OX40L pathway and induction of PD-L1 synergistically protects mouse islet allografts from rejection
    Li Tao
    Ma Rui
    Zhu Jiye
    Wang Fushun
    Huang Lei
    Leng Xisheng
    CHINESE MEDICAL JOURNAL, 2014, 127 (14) : 2686 - 2692
  • [8] PD-L1 Blockade for Cancer Treatment: MEDI4736
    Ibrahim, Ramy
    Stewart, Ross
    Shalabi, Aiman
    SEMINARS IN ONCOLOGY, 2015, 42 (03) : 474 - 483
  • [9] A Novel Designed Anti-PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity
    Li, Baocun
    Gong, Shiyong
    Zhang, Nianying
    Shi, Beilei
    Lv, Zhou
    Zhang, Yu
    Gaowa, Naren
    Dong, Liqin
    Wu, Danqing
    Wu, Jianfu
    Liu, Fan
    Zhang, Rui
    Behzadigohar, Ramin
    Ganju, Vinod
    Wu, Chengbin
    Wu, Xuan
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (03) : 317 - 330
  • [10] KN-052, a novel PDL1/OX40 bispecific antibody, exhibits potent antitumor efficacy
    Xu, Ting
    Wang, Pilin
    Fu, Yang-Xin
    Guo, Kangping
    Peng, Jianjian
    CANCER RESEARCH, 2023, 83 (08)
12345